Comparative efficacy of topical calcipotriol and tacrolimus in alopecia areata: A prospective trial
vitamin D analogues in alopecia areata
DOI:
https://doi.org/10.66344/jpad.v34i1.2404Keywords:
Alopecia areata, Calcipotriol, SALT score, TacrolimusAbstract
Introduction Alopecia areata (AA) is a non-scarring, inflammatory type of hair loss, ranging in severity from patchy hair loss to alopecia totalis and universalis. Various treatment modalities are available for alopecia areata, including topical, intralesional, and systemic steroids, minoxidil, and systemic immunosuppressive. Multiple studies demonstrated the variable efficacy of vitamin D analogs in alopecia areata, but none have compared them with topical tacrolimus.
Methods It was a randomized control trial conducted at Tehsil Headquarters Hospital TakhtBhai, Mardan. A total of 80 patients were enrolled in the study, 40 in each group. Using the technique of a consecutive non-probability sampling, patients were separated into groups A and B. Group A received topical calcipotriol (0.005%), while group B patients were treated with tacrolimus (0.1%). Both drugs were used twice a day for 6 months. Lesions were examined every month, and at the end of 6 months, a final SALT score was calculated.
Results In our study, group A had 52% males and 48% females, while group B had 49% males and 51% females. The mean age was 32.6±6.7 and 31.5±7.4 in Group A and B respectively. The mean baseline SALT score in group A was 14.3±5.2 while in group B was13±5.1. On the other hand, the mean SALT score after 6 months was 6.2±2.3 in Group A and 8.5±5.6 in Group B. The efficacy in Group A came out to be 67%, while in group B, 33% efficacy was noted (p-value=0.0132).
Conclusion This study found that topical calcipotriol is superior to topical tacrolimus for hair growth in patients with alopecia areata. The difference was statistically significant.
References
1. Shumez H, Prasad PV, Kaviarasan PK, Deepika R. Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: a comparative study. Int J Med Res Health Sci. 2015;4(1):118-22.
2. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):1-7.
3. Seetharam KA. Alopecia areata: An update. Indian J Dermatol Venereol Leprol. 2013;79:563.
4. Lundin M, Chawa S, Sachdev A, Bhanusali D, Seiffert-Sinha K, Sinha AA. Gender differences in alopecia areata. J Drugs Dermatol. 2014;13(4):409-13.
5. Abi Thomas E, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008;53(2):70.
6. Strazzulla LC, Wang EH, Avila L, Sicco KL, Brinster N, Christiano AM, Shapiro J. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1-2.
7. Messenger AG, Slater DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol. 1986;114(3):337-47.
8. Egawa K, Ono T. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol. 2004;150(2):374-6.
9. Demay MB, MacDonald PN, Skorija K, Dowd DR, Cianferotti L, Cox M. Role of the vitamin D receptor in hair follicle biology. J Steroid Biochem Mol Biol. 2007;103(3-5):344-6.
10. Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, Kim BJ, Kim MN. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012;24(3):341-4.
11. Lang PO, Aspinall R. Can we translate vitamin D immunomodulating effect on innate and adaptive immunity to vaccine response?. Nutrients. 2015;7(3):2044-60.
12. Clancy N, Onwuneme C, Carroll A, McCarthy R, McKenna MJ, Murphy N, Molloy EJ. Vitamin D and neonatal immune function. J Matern Fetal Neonatal Med. 2013;26(7):639-46.
13. van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1-2):93-101.
14. Lin X, Meng X, Song Z. Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy. Am J Trans Res. 2019;11(9):5285.
15. Reynolds NJ, Al‐Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002;27(7):555-61.
16. Heidt S, Roelen DL, Eijsink C, Eikmans M, Van Kooten C, Claas FH, Mulder A. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159(2):199-207.
17. Baksh S, Burakoff SJ. The role of calcineurin in lymphocyte activation. InSeminars in immunology 2000 Aug 1 (Vol. 12, No. 4, pp. 405-415). Academic Press.
18. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus–an anti‐inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721-30.
19. .King BA, Senna MM, Ohyama M, Tosti A, Sinclair RD, Ball S, Ko JM, Glashofer M, Pirmez R, Shapiro J. Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework. Dermatol Ther. 2022;12(4):825-34.
20. Cerman AA, Solak SS, Altunay İ, Küçükünal N. Topical Calcipotriol Therapy for Mild-to-Moderate Alopecia Areata: A Retrospective Study. J Drugs Dermatol. 2015;14(6):616-20.
21. Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study. Dermatol Ther. 2017;30(3):e12464.
22. Molinelli E, Campanati A, Brisigotti V, Sapigni C, Paolinelli M, Offidani A. Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of Alopecia Areata: an intra subject pilot study. Dermatol Ther. 2020;10:515-21
23. Gupta M, SinGh S, KHAN BH. Comparative Evaluation of Efficacy Between Topical Calcipotriol Used Along With Topical Clobetasol And Topical Clobetasol Monotherapy In Treatment Of Alopecia Areata: A Randomised Clinical Trial. J Clin Diagnost Res. 2021;15(4): WC05-WC08.
24. Hossain MS, Miah MT, Khan MZ, Khondker L, Hasan MR. Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. J Pak Assoc Dermatol. 2015;25(3):197-201.
25. Ullah F, Dawood M, Noor N, Hameed S. Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata. Pak J Med Health Sci. 2022;16(06):133.
26. Saleem A, Khan M, Mashori GR, SamdanI A, Kazmi SA. Comparison of effectiveness of topical tacrolimus and betamethasone with soft paraffin in the treatment of patchy alopecia areata. Pak J Med Sci. 2009;25(5):833-6.
27. Nassar A, Elradi M, Radwan M, Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study. J Cosmet Dermatol. 2023;22(4):1297-1303.
28. Herkal KC, Patil S, Yogeesh HR, Thimmappa RM, Cholachaguddar L. Study of therapeutic comparison of tacrolimus 0.1% and minoxidil 2% in alopecia areata. Our Dermatol Online. 2013;4(3):306-10.
29. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52(1):138-9.
30. Bimbi C, Kyriakou G, Wollina U. Occlusive treatment enhances efficacy of tacrolimus 0.1% in a pediatric patient with severe alopecia areata: Case report and literature review. Pediatr Dermatol. 2021;38(1):339-40.
31. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52(1):138-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Fahim, Hina Khoso, Jahangir Khan, Rabeeka Bakhtiar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
